New eye drug aims to stop diabetic vision loss
NCT ID NCT07588100
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This early-stage trial tests an experimental drug called RO7663498, given as an injection into the eye, for people with diabetic retinopathy. The main goal is to check safety and how the drug moves through the body. About 30 participants will receive multiple doses to see if it is well-tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RO7663498 (injected into the eye)
- What this could lead to
- If it works, this could point toward a new treatment to control diabetic retinopathy and prevent vision loss.
- What could go wrong
- This is a very early Phase 1 trial with only 30 people, focused on safety. It may not show any benefit, and eye injections carry risks like infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Global Research Management
RECRUITINGGlendale, California, 91204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI eye doctor: could software catch diabetic blindness sooner?
- Can eye scans reveal hidden clues about diabetes damage?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling
- Eye scans could spot Diabetes-Related vision damage years early